Showing posts with label FDA Breakthrough Therapy designation for PKC412 (midostaurin). Show all posts
Showing posts with label FDA Breakthrough Therapy designation for PKC412 (midostaurin). Show all posts
Monday, May 9, 2016

Novartis receives FDA Breakthrough Therapy designation for PKC412 (midostaurin)

›
Novartis announced today that the United States Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to PKC...